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THE CURRENT policies for cadaver 
kidney distribution were recently dis-
cussed in THE JOURNAL.! Questions 
about liver allocation are even more im-
portant, because there is not the option 
of artificial organ support.2 Two prin-
ciples of liver deployment have been ad-
vocated: efficiency of organ use and ur-
gency of need. 
THE EFFICIENCY PRINCIPLE 
Single Disease Studies 
Primary Biliary Cirrhosis.-Patients 
with this disease have been stratified 
retrospectively into low-, medium-, and 
high-risk categories, and their actual sur-
vival after liver transplantation has been 
compared with the outcome expected 
without such intervention." This com-
parison depended on a Mayo hazard pre-
diction model of the natural history of 
primary biliary cirrhosis (Table 1).4 Be-
fore the Kational Institutes of Health 
Consensus Development Conference of 
1983,5 we reserved liver transplantation 
candidacy for patients with chronic dis-
ea:-;e 'whose life expectancy was a few 
months.'i The effect of this restrictive 
policy could be seen in liver recipients 
treated for primary biliary cirrhosis be-
tween March 1980 and June 1987. Even 
in the low-risk group, the bilirubin level 
averaged 205 j,Lmol/L (12 mg/dL), and in 
the high-risk group, it averaged 480 
j,Lmol/L (28 mg/dL). All three cohorts 
had hypoalbuminemia (Table 1). 
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The 75% I-year patient survival rate 
after transplantation was a 30 percent-
age point gain over the 45% rate pre-
dicted with medical treatment.B Because 
I-year survival rates were 83%, 75%, 
and 58% in the low-, medium-, and high-
risk categories, respectively, the results 
haye been used to demonstrate the in-
efficient use of organs when they are 
transplanted to high-risk recipients. 
Viewed from a different perspective, the 
gain of survival in the first postopera-
tive year relative to projected outcome 
without transplantation was actually 
highest (58 percentage points) in the 
high-risk patients, next highest (55 per-
centage points) in the medium-risk 
group, and lowest (only 14 percentage 
points) in the low-risk group, whose 
I-year survival rate without interven-
tion would have been 69% (Fig 1). The 
life survival slope and degree of reha-
bilitation after 1 year were the same in 
all groupS.5 
Sclerosing Cholangitis.-Similar but 
more pronounced trends were seen with 
sclerosing cholangitis7 using a second 
Mayo hazard prediction model that fac-
tored in age, bilirubin level, spleno-
megaly, and histopathologic stage.8 The 
gain in I-year survival rate with trans-
plantation VB the predicted outcome 
without this procedure was only 7 per-
centage points in low-risk cases, a gain 
relative to the surrogate control that 
did not increase in the succeeding 7 years 
(Fig 2). In the medium-risk patients, the 
I-year survival dividend from transplan-
tation was zero, but this steadily in-
creased thereafter. In contrast, the high-
risk group achieved a stunning 40 per-
centage point life survival gain by 12 
months, an improvement that had grown 
to nearly 80 percentage points at 7 years, 
by which time all patients without trans-
plantation were long since projected 
dead. By 7 years, the best absolute sur-
vival rate belonged to the patients who 
originally had been the most ill (Fig 2). 
Heterogeneous Diseases: 
Risk Factors and Cost 
At the New England Medical Center, 
Boston, Mass, 124 adults and children 
who had a full spectrum of diagnoses 
and medical urgency were given 1421iv-
ers between 1984 and 1992. These cases 
illustrated the relationship between the 
severity of pretransplant illness, patient 
survival, and cost oftreatment.9 Urgency 
of need was determined with the 5-tier 
scale (called the United Network for 
Organ Sharing lUNOS] score) that was 
used nationally through 1990 (see leg-
end of Fig 8). UNOS 1 and 2 candidates 
(the least ill) had the highest rates of 
posttransplant survival (Fig 3). The 
poorest results were with the UN OS 4 
and 5 recipients. However, the rescue of 
the majority of these patients whose 
expected survival was essentially zero 
without transplantation was at least as 
noteworthy as the fact that the survival 
curve was degraded by their admission 
into candidacy. The cost of caring for 
the UNOS 4 and 5 recipients was high, 
reaching nearly $250000 and $190000 
per case, respectively, including the ex-
penditures before transplantation, which 
can exceed the expenses afterward. 
Poorer and more expensive results 
also were eyident when the high-risk 
patients were identified using the cri-
teria of the Blue Cross/Blue Shield con-
sortium or using the APACHE II (Acute 
Physiology and Chronic Health Evalu-
ation) score, which expresses pretrans-
plantation need for intensive care.9 No 
matter how sick the patients were be-
fore transplantation or how high the risk, 
however, those who lived (the majority 
in every subgroup) and were tested 1 
year later had the same degree of re-
habilitation, as determined by Karnof-
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Fig 5.-Patient and graft survival following primary orthotopic liver transplantation in adults, stratified by 
pre-1991 United Network for Organ Sharing (UNOS) risk categories. The difference between patient and 
graft survival is accounted for by successful retransplantation. 
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Fig 6.-lncreasing incidence of death while waiting with each increase of the United Network for Organ 
Sharing (UNOS) entry score of liver transplant candidates. The percentage of patients alive who had not 
received transplants decreased with increasing UNOS score. 
of the immunosuppressive drug, FK 506, 
which could be used for either primary 
or rescue treatmentY 
As expected, the best results were in 
the low-risk recipients. Few in number 
(n=12 [1.7%]), those in UNOS class 1 
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survived for 1 year at a rate of 91%; 
those in combined classes 1 and 2 at 
88%; those in class 5 (UNOStat [a life 
expectancy of only a few days without 
transplantation, often because of fulmi-
nant hepatic failure]) at 71 %; and those 
in classes 3 and 4 at rates in between 
(Fig 5, left). The incidence of retrans-
plantation was approximately the same 
in all cohorts, although it was less fre-
quently successful in the sickest patients, 
as reflected in the graft survival curve 
(Fig 5, right). The crucial observation 
was that the gap in results with differ-
ent urgency classes had narrowed to the 
point of nonsignificance except for the 
UNOStat group, which trailed the low-
risk groups by 17%. Still, 71% of even 
this highest-risk cohort was alive at 1 
year. After 1 year, the decline in sur-
vival rates was the same in all groups. 
Candidate Stability by UNOS Score 
The case flow after evaluation is sum-
marized in Fig 6. At the end of the first 
year, more than half (56%) of the pa-
tients who had entered as UNOS 1 can-
didates remained at this status, while 
3% had died. As the risk level at entry 
increased from UNOS 1 to UNOS 3, the 
population of patients who had trans-
plantations increased, frequently pre-
cipitated by worsening status and re-
classification. The death rate while wait-
ing was 10% for UNOS 3 patients and 
escalated to 17% for UNOS 4 patients 
and 28% for UNOS 5 patients (Fig 6)_ Of 
interest, 27 (3.4%) of the 796 patients in 
UNOS categories 3 through 5 improved 
enough with medical management to 
leave the hospital. These recoveries were 
dominated by patients with the entry 
diagnosis of fulminant hepatic failure. 
Termination of Trial 
These recipients, including those who 
were gravely ill at entry or whose con-
dition deteriorated while waiting, could 
be treated efficiently because ofthe em-
phasis on urgency of patient need and 
the national donor reservoir designed to 
meet this need. This was changed when 
a directive from UNOS, effective Janu-
ary 1, 1991, created a functional confed-
eracy in the United States of11 regions 
from which the free national movement 
of organs was discouraged in favor of 
'elective regional use. Urgency of need 
at a national level was removed as the 
most pervasive internal principle of the 
American organ allocation framework. 
CONSEQUENCES OF THE UNOS 
RULES CHANGE 
Loss of Patient Choice 
Factors that preclude candidacy at 
any given center, such as age, technical 
or medical complexity, or advanced ill-
ness, frequently are not contraindica-
tions in other centers to which rejected 
candidates can go for a second opinion. 
Under the new system, such patients no 
longer have easy access to a national 
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